US FDA Extends License of the GVK BIO Biomarker database
February 04th, 2013; Hyderabad, India: GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (USFDA). The GOBIOM database, which has the latest and recently updated information on all the biomarkers reported in various clinical and preclinical studies, will be beneficial to the USFDA in its Biomarker Qualification Process.
GVK Biosciences licenses its Biomarker Database to The Division of Cancer Prevention, National Cancer Institute
September 4th, 2012; Hyderabad, India: GVK Biosciences (GVK BIO), Asia's leading contract research organization announced today that it has licensed its popular clinical biomarker database (GOBIOM) to the prestigious Division of Cancer Prevention (DCP), National Cancer Institute (NCI).
Indiana CTSI partners with GVK Biosciences to provide national access to biomarkers database
June 08, 2011, Hyderabad: In an agreement facilitated by the Indiana Economic Development Corporation (IEDC) during a February economic mission to India, the Indiana Clinical and Translational Sciences Institute (CTSI) has partnered with GVK Biosciences, Asia's leading Contract Research Organization, to provide researchers across the United States access to GVK BIO's Clinical Biomarker Database that will advance research on wide range of diseases. The Indiana CTSI Bioinformatics Core and Indiana Institute for Personalized Medicine will work together to manage the process by which researchers access this new resource.
GVK Biosciences Partners with the PROOF Centre of Excellence, University of British Columbia in Biomarker Development and Commercialization
November 15th, 2011; Hyderabad, India: GVK Biosciences (GVK BIO), Asia's leading drug discovery research and development organization, announced today a new partnership with the PROOF Centre of Excellence, focusing on biomarker development for heart, lung and kidney failure.